Introduction {#Sec1}
============

Acute myocardial infarction (AMI) is often associated with activation of the circulating renin--angiotensin--aldosterone system (RAAS), which causes necrosis of cardiac myocytes and systemic vasoconstriction and affects left ventricular structure and function \[[@CR1]\]. Therefore, current guidelines recommend angiotensin-converting enzyme (ACE)-inhibitors to all patients with ST-segment elevation AMI (STEMI) and an impaired left ventricular ejection fraction (LVEF \< 40%), or those who have experienced heart failure (HF) in the early phase \[[@CR2], [@CR3]\]. A combination of ACE-inhibitors and acetylsalicylic acid (ASA) is often administered to improve outcomes in patients with left ventricular dysfunction (LVD), but potential negative interactions have questioned this approach.

This review will summarize the results from the SMILE-4 study, the clinical trial of SMILE program that specifically compared the effects of zofenopril or ramipril in combination with ASA in patients with LVD after AMI. Evidence from published data of the main study and subgroups, and unpublished data on the long-term effect of zofenopril and ramipril in the patients of the SMILE-4 study, will be summarized and critically presented. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Pharmacological Rationale of Zofenopril in the Treatment of AMI and HF {#Sec2}
======================================================================

Zofenopril is a sulfhydryl group-containing ACE-inhibitor, converted by esterases in the active metabolite zofenoprilat in both serum and tissues. The main feature of zofenopril is its high lipophilicity that favors a wide tissue distribution and a long duration of action \[[@CR4], [@CR5]\]. The time course of tissue distribution is characteristic for each molecule and varies among ACE-inhibitors: all ACE-inhibitors achieve an early and complete inhibition of the ACE in the blood, but their activity in other tissues is mainly associated with a selective distribution rather than with a different inhibitory potency. For instance, in the aorta, the inhibitory activity of zofenopril persists for more than 4 days and, as well as in cardiac tissue, zofenopril produces a long-lasting inhibition \[[@CR4]\]. The wide tissue distribution of zofenopril is even important for its pleiotropic effects on endothelial dysfunction, namely its anti-ischemic, anti-atherogenic, and pro-angiogenic properties \[[@CR6]\].

In addition to high lipophilicity, the presence of the sulfhydryl group in the zofenopril structure provides vascular protection and anti-atherogenic effects due to the ability to reduce the oxidative stress and activate the nitric oxide (NO) pathway \[[@CR7]\]; therefore, its role on peripheral vascular function is independent of ACE-inhibition \[[@CR8]\].

Numerous evidence in animal models supports that the cardioprotective role of zofenopril after AMI is associated with anti-oxidant and anti-atherogenic properties. In Watanabe heritable hyperlipidemic rabbits, zofenopril reduced plasmatic low-density lipoprotein (LDL) oxidation, the number of macrophages-derived foam cells, and the wall-associated platelet deposition at the site of atherosclerotic lesions \[[@CR9]\]. In rat models of ischemia and heart failure treated with zofenopril for 15 days (chronic model), zofenopril induced heat shock protein 70 expression and downregulated NO synthase 3, with a heart-specific effect on gene expression which partially explained an increased resistance to ischemia \[[@CR10]\]. Zofenopril significantly augmented both plasma and myocardial H~2~S (sulfane sulfur) and NO levels in mice and plasma H~2~S in pigs, substances that could scavenge radical oxygen substrates and prevent myocardial damages associated with the ischemia/reperfusion injury \[[@CR11]\].

Therefore, both in vitro and in vivo data support the rationale use of zofenopril in patients after AMI.

Clinical Efficacy of Zofenopril in AMI: the SMILE Program {#Sec3}
=========================================================

Zofenopril has been tested in an extensive clinical program to assess its effects on reduction of morbidity and mortality in patients after AMI. The SMILE (Survival of Myocardial Infarction Long-term Evaluation) studies involved more than 3600 patients in different settings (Table [1](#Tab1){ref-type="table"}): (1) early AMI (\< 24 h), not eligible for thrombolytic therapy because of late admission to the intensive care unit or with contraindication to systemic fibrinolysis (SMILE-1) \[[@CR12]\]; (2) confirmed diagnosis of AMI and a prior thrombolytic treatment within 12 h from the onset of clinical symptoms (SMILE-2) \[[@CR13]\]; (3) recent AMI (within 6 ± 1 weeks) with preserved LVEF (\> 40%), treated with thrombolytic treatment and ACE-inhibitors (SMILE-3) \[[@CR14]\]; and (4) early AMI (within 24 h), either treated with thrombolysis or not, with primary percutaneous transluminal angioplasty (PCTA) or coronary artery by-pass graft, and with clinical and/or echocardiographic evidence of left ventricular dysfunction (SMILE-4) \[[@CR15]\]. The program enrolled patients in almost all European Countries, thus providing data from subjects with different dietary and medical behaviours and in the context of different healthcare services; one-quarter of subjects enrolled were women.Table 1Summary of main characteristics of the SMILE studiesStudyInclusion criteriaIntervention (*n*)Control (*n*)Daily zofenopril doseControlTreatment duration (weeks)Post-treatment follow-up (years)Primary end-pointSMILE-1 \[[@CR12]\]Acute anterior myocardial infarction not eligible for thrombolytic therapy in the previous 12 h77278415--60 mgPlacebo61Occurrence of death or severe congestive heart failure over 6 weeksSMILE-2 \[[@CR13]\]Thrombolytic treatment within 12 h from acute myocardial infarction and SBP \> 100 mmHg50452015--60 mgLisinopril 2.5--10 mg daily6--Occurrence of severe hypotension (SBP \< 90 mmHg) at any timeSMILE-3 \[[@CR14]\]Myocardial infarction in the preceding 6 weeks with preserved left ventricular ejection fraction (\> 40%), prior thrombolysis and treatment with ACE-inhibitors17217715--60 mgPlacebo24--Global ischemic burden (ischemia on 24 h ambulatory ECG, ischemia or angina during treadmill test, recurrent myocardial infarction, need for revascularization)SMILE-4 \[[@CR15]\]Myocardial infarction in the previous 24 h treated or untreated with thrombolysis, CABG or PTCA, with clinical and/or echocardiographic evidence of left ventricular dysfunction36535115--60 mg plus ASA100 mg dailyRamipril 10 mg daily plus ASA100 mg daily485.5Occurrence of cardiovascular mortality or hospitalization for cardiovascular causes*SBP* systolic blood pressure, *CABG* coronary artery by-pass graft, *PTCA* percutaneous transluminal coronary angioplasty, *ASA* acetylsalicylic acid

In patients of the SMILE-1 Study with early AMI occurring within 24 h, zofenopril reduced the risk of death or severe congestive heart failure by 34% (95% CI, 8--54%; *p* = 0.018), and after 1 year of follow-up, reduced the risk of death by 29% (95% CI, 6--51%; *p* = 0.011), with a lower mortality rate than placebo (10.0% vs. 14.1%) \[[@CR12]\].

In the SMILE-2 Study, the safety of zofenopril treatment was compared to lisinopril in patients with different infarct sites who underwent thrombolytic therapy. Zofenopril, started within 24 h from symptoms onset, resulted as safe and well-tolerated and showed a rate of severe drug-related hypotension lower than lisinopril (6.7% vs. 9.8%, *p* = 0.048) \[[@CR13]\].

In the SMILE-3 Study, electrocardiographic (ECG) abnormalities were evaluated after 6 months of treatment with zofenopril or placebo in patients with LVEF \> 40%. Zofenopril decreased the rate of ST-T depression during both the ambulatory ECG and the exercise test, reduced the incidence of anginal pain, significant ST depression, and major ventricular arrhythmias, thus supporting its cardioprotective role when ventricular function was preserved \[[@CR14]\].

A pooled analysis of individual patient data from all the SMILE studies (the results of the SMILE-4 Study will be detailed and discussed in the next sections) further confirmed the efficacy of zofenopril in the post-AMI setting. Zofenopril reduced the risk of combined occurrence of death or hospitalization for CV causes, compared to placebo, and, at least in the long term, even compared to lisinopril and ramipril. The activity of zofenopril was evident immediately after starting the treatment and sustained over time: a risk reduction by 70% was achieved in the first 6 weeks, while an additional 30% was reached at the end of follow-up \[[@CR16]\].

Zofenopril and Ramipril in Combination with ASA in Patients with LVD Following AMI: the SMILE-4 Study {#Sec4}
=====================================================================================================

The SMILE-4 Study was designed to investigate the efficacy of zofenopril in combination with ASA \[[@CR15]\]. A combination with ACE-inhibitors and ASA is frequently used to treat patients with LVD, but some concerns about possible negative interactions have questioned this approach. In the SMILE-4 Study, patients were randomized to receive zofenopril or ramipril plus ASA (100 mg once daily). As primary outcome, the 1-year combined occurrence of mortality or hospitalization for cardiovascular (CV) disease was lower with zofenopril + ASA treatment than ramipril + ASA, with a reduction of risk by 30% (OR 0.70, 95% CI 0.51--0.96) (Fig. [1](#Fig1){ref-type="fig"}). Both systolic and diastolic blood pressure, median levels of NT-proBNP, improvement in LVEF, renal function deterioration, and non-CV adverse events were similar between treatments. Therefore, zofenopril + ASA was more efficient than ramipril + ASA in preventing the 1-year risk of death or hospitalization for CV causes \[[@CR15]\]. The difference in clinical efficacy among ACE-inhibitors in association with ASA might be related to the presence of the sulfhydryl group---present in zofenopril but not in ramipril---which confers cardioprotective effects by mechanisms other than prostaglandin-mediated signalling. As a matter of fact, in the SMILE-1 study, the relative risk reduction of death or severe congestive heart failure after 6 weeks of treatment with zofenopril versus placebo was not significantly different (*p* = 0.364) in the presence of (RR 0.77, 95% CI 0.45--1.30; *n* = 61) or in the absence of (RR 0.55, 95% CI 0.33--0.89; *n* = 77) concomitant ASA \[[@CR12]\].Fig. 1Cumulative incidence of the combined primary study endpoint (CV mortality or hospitalization for CV causes, including congestive heart failure, acute myocardial infarction, angina or decline in left ventricular ejection fraction \> 15%) (**a**) and of hospitalization (**b**) during the 1 year of treatment with zofenopril plus ASA (continuous lines, *n* = 365) or ramipril plus ASA (dashed lines, *n* = 351) in the SMILE-4 study. *p* value from the log rank statistics. *CV* cardiovascular.Redrawn from Ref. \[[@CR15]\] with permission

To further strengthen the results of the SMILE-4 Study, a propensity score analysis was performed to take into account some potential confounding factors related to population characteristics, rather than to the clinical impact of therapy \[[@CR17]\]. The propensity score was estimated based on 13 variables: age, gender, heart rate, concomitant diabetes, metabolic syndrome, hypercholesterolemia, low high-density lipoprotein (HDL), type of infarction, revascularization, Killip class, NT-proBNP, LVEF, and glomerular filtration rate. Data on these variables were available for all patients and were considered as representative of the individual's risk level. After adjusting for the propensity score, the superiority of zofenopril over ramipril was confirmed, with overlapping results with those reported in the original SMILE-4 study (OR 0.70, 95% CI 0.51--0.96, *p* = 0.028); the rate of major CV events was similar between propensity groups. However, a significantly lower risk of combined occurrence of death and hospitalization for CV causes was observed in patients in the third quintile of the propensity score, namely in patients who were at intermediate risk (Fig. [2](#Fig2){ref-type="fig"}). Based on this observation, subjects at intermediate risk may have more benefit from early treatment with zofenopril, whereas in other risk classes both treatments may be equally effective \[[@CR17]\].Fig. 2Cumulative survival free from CV events between zofenopril and ramipril within quintiles of propensity score at 1 year in the patients of the SMILE-4 study. The *p* values in each panel indicate the statistical significance of the between-treatment difference (log rank statistics). *Q* quintileRedrawn from Ref. \[[@CR17]\] with permission

Cost-Effectiveness Analysis of the SMILE-4 Study {#Sec5}
================================================

Once clinical efficacy and safety of zofenopril in combination with ASA was demonstrated, a pharmaco-economic analysis was performed to verify whether the added benefit of zofenopril was worth the added cost \[[@CR18]\]. Based on the reduction by 30% of the risk of death or hospitalization for CV causes with zofenopril compared to ramipril, a number needed to treat of 13 was calculated, thus indicating that one major CV event could be prevented by treating 13 patients fewer with zofenopril than with ramipril. The incremental cost-effectiveness ratio (ICER) for zofenopril compared to ramipril was 2125.45 euros for any additional event prevented. The analysis included costs derived from drug purchase and hospitalization or events (Table [2](#Tab2){ref-type="table"}); the perspective adopted for the study was that of a third-party payer. The information on costs of medications were derived from the national pharmaceutical formulary of each country, while the costs for post-AMI events were calculated considering a Diagnosis-Related Group Code \[[@CR19]\]. Therefore, the cost-effectiveness of zofenopril was favorable compared to ramipril, a drug already proven to be cost-effective in patients at high risk of CV disease \[[@CR20]\], and thus zofenopril could be placed among viable and cost-effective options for managing patients with LVD.Table 2Unit and overall costs for treating each single event in the SMILE-4 StudyFrom Ref. \[[@CR18]\] with permissionType of outcomeCost per event per patient (euros)Zofenopril (*n* = 365)Ramipril (*n* = 351)No. of eventsTotal cost (euros)No. of eventsTotal cost (euros)Congestive heart failure3425.51413,702.04723,978.57Acute myocardial infarction4019.041352,247.521664,304.64Angina pectoris2642.242052,844.802258,129.28Decline in LVEF \> 15%1141.841517,127.552831,971.43Revascularization10,993.1425274,828.3832351,780.32Other causes3650.201140,152.201243,802.40Death4257.641772,379.881146,834.04Overall cost523,282.37620,800.68Average cost per patient4983.644850.01Number of occurrences for each outcome are also indicated*LVEF* left ventricular ejection fraction

Subgroup Analyses of High-Risk Patients of the SMILE-4 Study {#Sec6}
============================================================

The wide population of the SMILE-4 Study offers the opportunity to evaluate the efficacy of zofenopril in peculiar subgroups of patients, including hypertensive and diabetic subjects and those with preserved ventricular function (Table [3](#Tab3){ref-type="table"}). Before discussing these results obtained in specific subgroups, the post hoc nature of these analyses must be remembered and thus the need of future prospective evaluation of zofenopril versus ramipril in these subgroups taking into account adequate sample sizes and appropriate inclusion/exclusion criteria.Table 3Absolute and relative frequency (%), adjusted odds ratio (95% confidence interval) and corresponding *p* value of 1-year combined occurrence of death or hospitalization for CV causes, of 1-year CV hospitalization and 1-year CV death in subgroups of patients of the SMILE-4 studyFrom Ref. \[[@CR15]\] with permissionZofenopril\
*n* (%)Ramipril\
*n* (%)Adjusted odds ratio (95% confidence interval)*p* valueArterial hypertension 1-year combined end-point84/273 (30.8)99/252 (39.3)0.64 (0.43, 0.96)0.031 1-year CV hospitalization71/260 (27.3)90/243 (37.0)0.61 (0.40, 0.92)0.017 1-year CV mortality13/273 (4.8)9/252 (3.6)1.37 (0.57, 3.30)0.484Diabetes mellitus 1-year combined end-point21/68 (30.9)26/63 (41.3)0.56 (0.18, 1.73)0.313 1-year CV hospitalization16/63 (25.4)23/60 (38.3)0.38 (0.15, 0.95)0.038 1-year CV mortality5/68 (7.4)3/63 (4.8)8.57 (0.57, 128.04)0.120Preserved LVEF (\> 40%) 1-year combined end-point48/213 (22.5)77/235 (32.8)0.59 (0.39, 0.91)0.015 1-year CV hospitalization45/210 (21.4)74/232 (31.9)0.58 (0.38, 0.89)0.013 1-year CV mortality3/213 (1.4)3/235 (1.3)1.11 (0.22, 5.53)0.904*CV* cardiovascular, *LVEF* left ventricular ejection fraction

Hypertension is an independent negative prognostic risk factor for AMI and, after AMI, for the incidence of CV adverse events, likely due to endothelial damage, atherosclerosis, insulin resistance, left ventricular hypertrophy, and ventricular arrhythmias, increases \[[@CR21]\]. In the SMILE-4 Study, 525 (77%) patients were classified as hypertensives \[[@CR22]\]. These patients were older, more often females, with higher prevalence of comorbidities, such as diabetes mellitus, hyperlipidemia, angina pectoris, heart failure, and chronic renal failure than normotensives, but were submitted less frequently at entry to PTCA than normotensives. The combined occurrence of death or hospitalization for CV causes was similar between normotensive and hypertensive patients; however, the effects of zofenopril in reducing the risk of the combined end-point (OR 0.64, 95% CI 0.43--0.96) and the hospitalization for major CV events (OR 0.61, 95% CI 0.40--0.92) compared to ramipril were significantly higher in hypertensive patients (*p* = 0.031 for the combined end-point and *p* = 0.017 for mortality; Table [3](#Tab3){ref-type="table"}). The superiority of zofenopril was particularly striking in the high-risk subgroup of patients with isolated systolic hypertension (OR 0.48, 95% CI 0.23--0.99, *p* = 0.045; Fig. [3](#Fig3){ref-type="fig"}). Such effects of zofenopril may be prevalently related to ancillary properties of the drug on the remodelling process and endothelial dysfunction, rather than to its antihypertensive action because the magnitude of blood pressure reduction of zofenopril and ramipril was similar \[[@CR22]\].Fig. 3Cumulative survival without events during 1-year in patients of the SMILE-4 study with isolated systolic hypertension treated with zofenopril (continuous line) or ramipril (dotted line). *p* value from the logistic regression analysis. *OR* odds ratio, *CI* confidence intervalRedrawn from Ref. \[[@CR22]\] with permission

Diabetes is another comorbidity highly present in the post-AMI setting which increases the risk of developing LVD and worsens congestive HF \[[@CR23], [@CR24]\]. Zofenopril shows favorable features that may confer potential advantages in patients with AMI complicated by congestive HF. A post hoc analysis of the SMILE-1 study indicated that the efficacy of an early treatment with zofenopril was higher in diabetic patients than in non-diabetic ones, in terms of the reduction of the combined incidence of death and severe congestive HF, with decreased incidence of congestive HF alone and improved early survival rate \[[@CR25]\]. In the SMILE-4 study, in which diabetic patients represented 19% of the population, zofenopril had a larger effect than ramipril in reducing the combined occurrence of death or hospitalization in patients with diabetes (OR 0.56, 95% CI 0.18--1.73), although the between-treatment difference was not statically significant (*p* = 0.313). Conversely, the reduction in the rate of hospital admission for CV causes was significantly larger under zofenopril (OR 0.38, 95% CI 0.15--0.95, *p* = 0.038) (Table [3](#Tab3){ref-type="table"}) \[[@CR26]\]. The larger effect of zofenopril over ramipril was particularly evident in patients with uncontrolled blood glucose (≥ 126 mg/dL), regardless of the previous diagnosis of diabetes (Fig. [4](#Fig4){ref-type="fig"}). However, in diabetic patients, no superiority of zofenopril was observed in terms of risk reduction of CV mortality (Table [3](#Tab3){ref-type="table"}; Fig. [4](#Fig4){ref-type="fig"}). These results are remarkable because the association between diabetes, glucose abnormalities, or impaired glucose intolerance and poor outcomes is well documented \[[@CR27], [@CR28]\]; zofenopril may contribute to prevent major adverse cardiovascular events in diabetic patients post-AMI who are at further risk.Fig. 4Prevalence (%) of 1-year combined occurrence of death or hospitalization for CV causes, of 1-year CV hospitalization and 1-year CV death in patients of the SMILE-4 study with elevated baseline blood glucose (≥ 126 mg/dL) regardless of the presence or absence of diabetes, treated with zofenopril (open bars) or ramipril (full bars). Adjusted odds ratio and 95% confidence intervals, and *p* values are shown. *CV* cardiovascularRedrawn from Ref. \[[@CR26]\] with permission

In the SMILE-4 Study, 63% of patients had a LVEF \> 40% \[[@CR15], [@CR29]\]: data from this population may be useful in the controversy about the use of ACE-inhibitors in patients with preserved LVEF, even if current guidelines consider it as reasonable \[[@CR2], [@CR3]\]. During the study, all patients underwent a standard echocardiographic examination, with determination of LVEF and left ventricular systolic and diastolic volumes, as recommended by the American Society of Echocardiography \[[@CR30]\]. Patients with preserved LVEF had a lower prevalence of anterior infarct, higher frequency of PTCA at the admission, higher levels of glomerular filtration rate, and lower values of NT-proBNP and heart rate \[[@CR15], [@CR29]\]. In these patients, zofenopril confirmed its superiority over ramipril with a reduction of combined death and hospitalization for CV causes by 41% (OR 0.59, 95% CI 0.39--0.91, *p* = 0.015) (Table [3](#Tab3){ref-type="table"}). Consistently with previous results, the reduction in the hospital rate drove the difference between treatments, but the number of deaths in the preserved LVEF group was too small (3 patients in each arm) to provide a conclusive evidence (Table [3](#Tab3){ref-type="table"}). Therefore, the efficacy of zofenopril in patients with HF without ECG signs of left ventricular dysfunction may differ from other ACE-inhibitors and the number of patients needed to treat to prevent additional death may be different in patients with preserved or impaired LVEF.

Long-Term Efficacy of Zofenopril and Ramipril in Post-AMI Patients: The SMILE-4 Follow-Up {#Sec7}
=========================================================================================

The SMILE-4 Study lasted from March 2005 to July 2009 \[[@CR15]\]; in 2012, the investigators designed a further follow-up phase to investigate the long-term benefits of early treatment after AMI with zofenopril + ASA or ramipril + ASA \[[@CR31]\]. The survival analysis started on the date of entry into the original study; therefore, a median follow-up of 5.5 years was considered. During this time, 28.9% of patients maintained the originally assigned treatment, 34.9% switched to the other study drug, and 36.2% used other ACE-inhibitors, different from zofenopril or ramipril. Furthermore, during the maintenance therapy, dosing was likely different from the initial 60 mg of zofenopril and 10 mg of ramipril. Both switching and different dosing represented confounding factors to determine the occurrence of CV death or hospitalization during the follow-up; however, on the other hand, these changes strengthened the role on long-term outcomes of early treatment after AMI. Zofenopril maintained its superiority in reducing the combined occurrence of death or hospitalization for CV causes over ramipril (27.8% vs. 43.8%) and in increasing the survival likelihood after AMI (OR 0.65, 95% CI 0.43--0.98, *p* = 0.041) (Fig. [5](#Fig5){ref-type="fig"}). The rate of hospital admission was significantly lower with zofenopril (OR 0.61, 95% CI 0.37--0.99, *p* = 0.047). Interestingly, as shown in Fig. [6](#Fig6){ref-type="fig"}, which reports unpublished data from the SMILE-4 follow-up, long-term event-free survival was better in patients originally randomized to zofenopril and continuing the originally assigned treatment or originally treated with ramipril and switched to zofenopril in the course of the years than in patients continuing treatment with ramipril. These follow-up data indicated that an early treatment with zofenopril after AMI offered more favorable long-term effects than that with ramipril and confirmed that a combination with ASA did not affect the clinical outcomes of ACE inhibitors.Fig. 5Incidence of CV mortality or hospitalization for CV causes (**a**), CV death (**b**) or CV hospitalization (**c**) during the follow-up in patients originally randomized and treated with zofenopril (continuous lines, *n* = 144) or ramipril (dashed lines, *n* = 121) in the SMILE-4 study. *p* value from the log rank statistics. *CV* cardiovascular.Redrawn from \[[@CR31]\] with permission Fig. 6Cumulative survival without CV events in the SMILE-4 follow-up. Data are separately shown for patients originally randomized and treated with zofenopril or ramipril, and continuing the original randomized treatment (continuous line), switching to the other randomized treatment (dashed line) or switching to other ACE-inhibitors (dotted line). *p* values from the log rank statistics. *CV* cardiovascular, *ACE* angiotensin converting enzyme

Effects of Zofenopril and Ramipril on Mortality in Patients with Chronic HF in the Clinical Practice Setting {#Sec8}
============================================================================================================

Pharmacoepidemiologic data from real-world settings have indicated that ramipril was associated with better outcomes on HF prognosis, compared to enalapril and captopril \[[@CR32]\]. Based on SMILE-4 post-AMI results of zofenopril and ramipril, these two drugs were head-to-head-tested in patients with chronic HF to evaluate the outcomes in mortality in clinical practice \[[@CR33]\]. In the overall population, mortality was similar among patients who received zofenopril (45 deaths from 102 patients) or ramipril (48 deaths from 73 patients), but zofenopril was a significant predictor of survival in patients older than 76 years (OR 0.56, 95% CI 0.35--0.91), in men (OR 0.57, 95% CI 0.30--0.98), and in patients with ejection fraction lower than 54% (OR 0.52, 95% CI 0.26--0.97) (Fig. [7](#Fig7){ref-type="fig"}). These subcategories of patients were those, a priori, with a greater probability of readmittance to hospital because of HF \[[@CR34]\], and those with greater costs for their management \[[@CR35]\].Fig. 7Cumulative survival in heart failure patients according to treatment with zofenopril (continuous line) or ramipril (dotted line). Data are shown for the whole study sample and according to male gender, old age (\> 76 years) and low left ventricular ejection fraction (\< 54%)Redrawn from Ref. \[[@CR33]\] with permission

Conclusion {#Sec9}
==========

Early treatment with zofenopril after AMI shows major clinical benefits in patients with LVD compared with ramipril: the effects are sustained over time, with a reduction of hospitalization for CV cause and death for at least 5 years, and the therapy is cost-effective. The combination with ASA does not seem to affect the antihypertensive activity of zofenopril and its ancillary properties, mainly associated with cardiac and vascular protection. Overall, the results of the SMILE-4 study highlight the superiority of zofenopril over ramipril in combination with ASA, at least in terms of the prevention of cardiovascular hospitalization, and support the early use of zofenopril immediately after AMI. The efficacy of zofenopril was also good in the presence of comorbidities, such as hypertension and diabetes, and in case of preserved ventricular function, though its superiority versus ramipril was only marginal and not always statistically significant, as in the whole study population. In the post-AMI setting, zofenopril should be maintained and may be useful to reduce the risk of HF, especially in men and elderly patients.
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